2K
2K3.F SI-BONE Inc
- Market cap
- EUR 789M
- P/E
- -
- P/B
- 4.80x
- ROE
- -8.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 2K3.F undervalued?
Graham numberThe Graham number of SI-BONE Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SI-BONE Inc fundamental analysis
No fundamental analysis for SI-BONE Inc yet.
SI-BONE Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SI-BONE Inc
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the j…
Full company profileSI-BONE Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SI-BONE Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 42.1M | 48.0M | 55.4M | 67.3M | 73.4M | 90.2M | 106M | 139M | 167M | 201M | 219M |
| Gross Profit | 36.9M | 42.9M | 50.5M | 60.5M | 64.5M | 79.7M | 90.7M | 109M | 132M | 160M | 174M |
| Operating Income | -17.6M | -17.4M | -12.0M | -36.0M | -38.6M | -51.7M | -59.6M | -46.9M | -35.2M | -22.3M | -19.0M |
| EBITDA | - | -15.8M | -11.6M | -32.7M | -36.5M | -49.1M | -55.0M | -34.4M | -23.1M | -10.5M | -7.01M |
| Net Income | -20.6M | -23.0M | -17.5M | -38.4M | -43.7M | -56.6M | -61.3M | -43.3M | -30.9M | -18.9M | -16.1M |
| EPS | - | -1.00 | -0.71 | -1.53 | -1.34 | -1.68 | -1.76 | -1.06 | -0.73 | -0.43 | -0.36 |
| Balance Sheet | |||||||||||
| Total Assets | 39.4M | 35.8M | 139M | 117M | 223M | 191M | 158M | 230M | 230M | 239M | 257M |
| Total Liabilities | 148M | 165M | 48.3M | 54.0M | 53.8M | 56.1M | 59.3M | 61.1M | 63.5M | 61.0M | 72.1M |
| Shareholders' Equity | -109M | -129M | 90.2M | 63.0M | 169M | 134M | 98.3M | 169M | 167M | 178M | 185M |
| Cash & Short-term Investments | 27.9M | 22.4M | 25.1M | 10.4M | 53.6M | 63.4M | 20.7M | 33.3M | 34.9M | 42.2M | 35.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.8M | -17.5M | -14.5M | -31.6M | -30.7M | -39.5M | -41.7M | -18.7M | -12.4M | -675K | 5.81M |
| Capital Expenditure | 441K | 478K | 942K | 2.45M | 2.56M | 6.39M | 9.51M | 7.80M | 10.5M | 8.41M | 12.0M |
| Free Cash Flow | - | -18.0M | -15.5M | -34.1M | -33.2M | -45.9M | -51.2M | -26.5M | -22.9M | -9.09M | -6.18M |
| Ratios | |||||||||||
| ROE | - | - | -19.4% | -60.9% | -25.8% | -42.1% | -62.3% | -25.6% | -18.5% | -10.6% | -8.7% |
| ROA | -52.2% | -64.3% | -12.6% | -32.8% | -19.6% | -29.7% | -38.9% | -18.8% | -13.4% | -7.9% | -6.3% |
| Net Profit Margin | -48.9% | -48.0% | -31.5% | -57.1% | -59.5% | -62.8% | -57.6% | -31.2% | -18.5% | -9.4% | -7.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SI-BONE Inc dividends
SI-BONE Inc has not paid dividends in the last 9 fiscal years.
Who owns SI-BONE Inc
- Insiders 3.15%
- Institutions 96.85%
- Public & others 0.00%
- Shares outstanding 45.1M
- Free float 40.5M
SI-BONE Inc company profile
- Company name
- SI-BONE Inc
- Ticker
- 2K3.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 376
- Fiscal year end
- December
- Address
- 471 El Camino Real, Santa Clara, CA, United States, 95050
- Phone
- 408 207 0700
- Website
- si-bone.com
About SI-BONE Inc
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
SI-BONE Inc management
10- Mr. Jeffrey W. DunnExecutive Chairman · born 1956
- Ms. Laura A. Francis MBACEO & Director · born 1967
- Mr. Anshul MaheshwariCOO & CFO · born 1980
- Mr. Michael A. Pisetsky J.D.Chief Business & Legal Affairs Officer, Secretary and General Counsel
- Mr. Anthony J. RecuperoAdvisor · born 1960
- Dr. Scott A. Yerby Ph.D.Senior VP of Engineering & CTO · born 1968
- Mr. Ian BaileyVice President of Product & Marketing
- Dr. Daniel Joseph Cher M.D.Senior Vice President of Clinical, Regulatory Affairs & Quality · born 1965
- Dr. W. Carlton Reckling M.D.Chief Medical Officer & VP of Medical Affairs · born 1963
- Mr. Nikolas F. KerrChief Commercial Officer · born 1972